Amplia Therapeutics Limited [ASX:ATX] share price and news 2022

Company Description

Amplia Therapeutics Limited (ATX, formerly Innate Immunotherapeutics Limited) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Amplia Therapeutics Limited belongs to Health Care sector and under industry of Biotechnology. You can get more information about this company via their website: http://www.ampliatx.com.

This a small cap company with market cap of 25 millions.

Compared to Market and Sector

The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.

Company PE is less than both sector and market. while On the other hand, Company Earning is less than both sector and market.

Earnings PE PB PE growth
Company 0 0 2 0
Market 0.85 22.3 1.99 0.84
Sector 1.7 39.6 5.78 0.26

Dividend Growth Chart

The following chart shows you how atx dividend grows in the recent years.

No data